Odaily Noon News
1. CRCL has been removed from several Russell Growth Indexes, including Russell 1000 and Russell 3000;
2. dYdX may launch a new product, with its token surging over 35% at one point;
3. Samsung Electronics announced 2nm process technology and an AI semiconductor ecosystem cooperation plan;
4. "White-haired stock god" Serenity: Semiconductor supply chain bottlenecks are intensifying, packaging and testing companies are raising prices;
5. SIVE completed a new round of financing of 700 million Swedish krona, and Serenity stated it may be entering a turning point for large-scale growth;
6. On Polymarket, the probability that "Claude Fable 5 will resume service for U.S. customers before July 1" has risen to 97%, up 71% in 24 hours;
7. After previously making over $7.7 million in profit, a whale leveraged 1x long on 16,704 ZEC;
8. After holding for more than 5 months and losing $4.33 million, a whale sold 2,468 ETH.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
